TNFRSF1B and neoplasm: In non-small cell lung cancer, combination therapy with PD-1 inhibitors, PTP1B inhibitors, and TNFR2 antibodies increased the proportion of CD8 T cells and reduced the proportion of Treg cells in the spleen, lymph nodes, and tumors of NSCLC models compared to monotherapy, effectively inhibiting tumor growth (54).